[go: up one dir, main page]

EP4069244A4 - USING REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS - Google Patents

USING REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS Download PDF

Info

Publication number
EP4069244A4
EP4069244A4 EP20895126.9A EP20895126A EP4069244A4 EP 4069244 A4 EP4069244 A4 EP 4069244A4 EP 20895126 A EP20895126 A EP 20895126A EP 4069244 A4 EP4069244 A4 EP 4069244A4
Authority
EP
European Patent Office
Prior art keywords
reboxetine
nervous system
system disorders
treat nervous
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20895126.9A
Other languages
German (de)
French (fr)
Other versions
EP4069244A1 (en
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,329 external-priority patent/US20200147093A1/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Priority claimed from PCT/US2020/062560 external-priority patent/WO2021113163A1/en
Publication of EP4069244A1 publication Critical patent/EP4069244A1/en
Publication of EP4069244A4 publication Critical patent/EP4069244A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20895126.9A 2019-12-03 2020-11-30 USING REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS Pending EP4069244A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962943077P 2019-12-03 2019-12-03
US201962946295P 2019-12-10 2019-12-10
US16/740,329 US20200147093A1 (en) 2018-10-15 2020-01-10 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,409 US11351175B2 (en) 2018-10-15 2020-01-11 Use of reboxetine to treat narcolepsy
US16/740,411 US20200147096A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,410 US20200147095A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
PCT/US2020/062560 WO2021113163A1 (en) 2019-12-03 2020-11-30 Use of reboxetine to treat nervous system disorders

Publications (2)

Publication Number Publication Date
EP4069244A1 EP4069244A1 (en) 2022-10-12
EP4069244A4 true EP4069244A4 (en) 2023-12-20

Family

ID=81851750

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20895126.9A Pending EP4069244A4 (en) 2019-12-03 2020-11-30 USING REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS

Country Status (12)

Country Link
EP (1) EP4069244A4 (en)
JP (1) JP2023504685A (en)
KR (1) KR20220108122A (en)
CN (1) CN114746097A (en)
AU (2) AU2020395082A1 (en)
BR (1) BR112022010677A2 (en)
CA (1) CA3163505A1 (en)
CO (1) CO2022007507A2 (en)
CR (1) CR20220247A (en)
IL (1) IL293536A (en)
MX (1) MX2022006630A (en)
PE (1) PE20230181A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL197983B1 (en) * 1999-07-01 2008-05-30 Upjohn Co Application of optically pure (S,S)-reboxetine and the pharmaceutically acceptable salts thereof for drug preparation
ATE319453T1 (en) * 1999-07-01 2006-03-15 Pharmacia & Upjohn Co Llc REBOXETINE FOR THE TREATMENT OF FIBROMYALGIA AND OTHER SOMATOFORM DISORDERS
EP2167066B1 (en) * 2007-05-07 2013-06-26 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders
KR102192554B1 (en) * 2013-03-13 2020-12-18 에스케이바이오팜 주식회사 Treatment of cataplexy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GARCIA-BORREGUERO D ET AL: "567.K Effects of reboxetine in narcolepsy-cataplexy: Preliminary findings on 14 patients", SLEEP; 15TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES; CHICAGO, ILLINOIS, USA; JUNE 05-10, 2001, ALLEN PRESS, LAWRENCE, KS, US, vol. 24, no. Abstract Supplement, 15 April 2001 (2001-04-15), pages A323 - A324, XP009531711, ISSN: 0161-8105 *
O' GORMAN CEDRIC ET AL: "SCIENTIFIC RATIONALE AND CLINICAL DEVELOPMENT OF AXS-12 FOR NARCOLEPSY", SLEEP, vol. 42, no. Abstract Supplement, 1 January 2019 (2019-01-01), pages A24, XP055866024 *
SCHMIDT CHRISTIAN ET AL: "The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 308, 23 April 2016 (2016-04-23), pages 205 - 210, XP029542431, ISSN: 0166-4328, DOI: 10.1016/J.BBR.2016.04.033 *
See also references of WO2021113163A1 *

Also Published As

Publication number Publication date
CN114746097A (en) 2022-07-12
CO2022007507A2 (en) 2022-06-21
MX2022006630A (en) 2022-06-24
EP4069244A1 (en) 2022-10-12
PE20230181A1 (en) 2023-02-01
CA3163505A1 (en) 2021-06-10
KR20220108122A (en) 2022-08-02
CR20220247A (en) 2022-08-18
BR112022010677A2 (en) 2022-08-16
AU2020395082A1 (en) 2022-06-09
AU2024203676A1 (en) 2024-06-20
JP2023504685A (en) 2023-02-06
IL293536A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
EP3618824A4 (en) USING N-ACETYLCYSTEINE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS
EP3952982C0 (en) VAGUOUS NERVE STIMULATION SYSTEM TO TREAT NEURODEGENERATIVE DISORDERS
EP2323667A4 (en) MODULATION OF TRANSTHYRETIN EXPRESSION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS
EP3389725A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP3139914C0 (en) COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS
EP2852388A4 (en) COMPOUNDS AND METHODS OF USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS
EP3525735A4 (en) THERAPEUTIC ULTRASOUND FOR EYE DISORDERS
EP3465212A4 (en) REGULATION OF THE INTESTINAL MICROBIOTE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
EP3713558A4 (en) AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS
MA51046A (en) 21- [4-CYANO-PYRAZOL-1-YL] -19-NOR-PREGAN-3 DERIVATIVES. ALPHA-OL-20-ONE DEUTERATES FOR THE TREATMENT OF CNS DISORDERS
EP3445451A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LYSOSOMAL DISORDERS AND DISORDERS CHARACTERIZED BY LYSOSOMAL DYSFUNCTION
EP2970099A4 (en) SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS
EP3692023A4 (en) BENZOTHIAZOL COMPOUNDS AND METHODS OF USING THEM TO TREAT NEURODEGENERATIVE DISORDERS
EP2782566A4 (en) L-SERINE COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS
MA42953A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
EP3352755A4 (en) NOVEL COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP2435563A4 (en) MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM
EP3893988A4 (en) NEUROMODULATION THERAPY FOR AUTOIMMUN AND INFLAMMATORY DISORDERS
MA49140A (en) MERGED HETEROAROMATIC-ANILINE COMPOUNDS FOR THE TREATMENT OF DERMAL DISORDERS
EP3638316A4 (en) GENE THERAPY FOR EYE DISORDERS
MA39927A (en) GLYT1 INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS
EP3866768A4 (en) USING REBOXETINE TO TREAT NARCOLEPSY
EP2897632A4 (en) USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTAID RELEASE OF CONNEXIN AND PANNEXINE HEMICANALS WITHOUT INFLUENCING COMMUNICABLE JUNCTIONS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
MA53437A (en) USE OF ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISORDERS, INCREASE NEUROPLASTICITY AND PROMOTE NEUROPROTECTION
EP2723339A4 (en) COMPOUNDS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES AND OTHER NEURODEGENERATIVE DISORDERS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080135

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

A4 Supplementary search report drawn up and despatched

Effective date: 20231122

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20231116BHEP

Ipc: A61P 25/00 20060101ALI20231116BHEP

Ipc: A61P 25/24 20060101ALI20231116BHEP

Ipc: A61K 31/5375 20060101AFI20231116BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250616